IL13RA2 and glioblastoma: A study by Yin and co-workers showed that BiTE-secreting T cells EGFR and interleukin-13 receptor alpha 2 (IL13Rα2) exhibited superior antitumour activity with higher sensitivity and specificity compared to their CAR-T counterparts in glioblastoma model (192).